# US 5,707,622 A · Methods for treating ulcerative colitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,707,622 A
- Document ID: US5707622A
- Status: Granted
- Kind: A
- Application number: 08/396,851
- Filed: 1995-03-01
- Granted: 1998-01-13
- Earliest claimed: 1994-03-03
- Assignees: Genentech, Inc.
- Inventors: Sherman Fong; Caroline Alice Hebert; Kyung Jin Kim; Steven R. Leong
- Web page: https://patentgrep.com/patent/US5707622A

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Anti-IL-8 monoclonal antibodies are described for use in diagnostic applications and in the treatment of inflammatory disorders such as inflammatory bowel disease and bacteria pneumonias.

## Claims

### Claim 1

A method of treating ulcerative colitis in a mammal comprising administering to the mammal a therapeutically effective amount of an anti-IL-8 monoclonal antibody having the following characteristics: ability to bind human IL-8 with a Kd between about 1.times.10.sup.-8 to about 1.times.10.sup.-11 M, ability to inhibit neutrophil chemotaxis in response to IL-8, and ability to inhibit IL-8 mediated elastase release by neutrophils: wherein the monoclonal antibody does not bind to C5a, .beta.-TG or platelet factor 4.

### Claim 2 (depends on 1)

The method of claim 1 wherein the mammal is a human.

### Claim 3 (depends on 1)

The method of claim 1 wherein the antibody is administered systemically.

### Claim 4 (depends on 1)

The method of claim 1 wherein the antibody is administered by continuous infusion.

### Claim 5 (depends on 1)

The method of claim 1 wherein the antibody is administered by bolus dosage.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antibody comprises an antigen binding site comprising the complementarity determining regions of the light chain polypeptide of FIG. 24 (SEQ ID NO:48) and the complementarity determining regions of the heavy chain polypeptide of FIG. 25 (SEQ ID NO:50).

### Claim 7 (depends on 1)

The method of claim 1, wherein the antibody comprises an antigen binding site comprising the complementarity determining regions of the light chain polypeptide of FIG. 16 (SEQ ID NO:20) and the complementarity determining regions of the heavy chain polypeptide of FIG. 17 (SEQ ID NO:22).